Generic Name and Formulations:
Dicyclomine HCl 10mg caps; 20mg tabs.
Indications for BENTYL:
Irritable bowel syndrome.
Initially 20mg 4 times daily; after 1 week may increase to 40mg 4 times daily if tolerated. Discontinue if not effective within 2 weeks or daily doses ≥80mg are not tolerated.
<6months: see Contraindications. ≥6months: consult manufacturer.
Glaucoma. Unstable cardiovascular status. GI or urinary tract obstruction. Severe ulcerative colitis. Myasthenia gravis. Reflux esophagitis. Children <6months of age. Nursing mothers.
Inj: avoid IV administration (may cause thrombosis, inj site reactions). Autonomic neuropathy. Hepatic or renal impairment. Cardiovascular disease. Hypertension. Hyperthyroidism. Salmonella dysentery. Toxic megacolon. Ulcerative colitis. GI or GU obstruction. High environmental temperature. Diarrhea. Elderly. Debilitated. Pregnancy (Cat.B).
Antacids may inhibit absorption; avoid. May antagonize anti-glaucoma agents or drugs that alter GI motility (eg, metoclopramide). Antagonized by agents used to treat achlorhydria and those used to test gastric secretion. Additive anticholinergic effects with other anticholinergics, narcotic analgesics, type I antiarrhythmics, antihistamines, antipsychotics, tricyclics, amantadine, benzodiazepines, MAOIs, nitrites, nitrates, sympathomimetics. May affect absorption of sust rel dosage forms.
Dizziness, dry mouth, blurred vision, nausea, somnolence, asthenia, and nervousness; cardiovascular and CNS symptoms (eg, psychosis, delirium). Fatal reactions have occurred in infants.
Caps, tabs—100; Syrup—contact supplier; Amps (2mL)—5
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry
- Medical Schools Phase Out Lectures as Education Shifts Outside the Classroom
- Clonidine Testing Is Safe and Reliable for Diagnosing Growth Hormone Deficiency